Active immunisation of adults & childn ≥6 mth of age for the prevention of influenza disease caused by 2 influenza A virus subtypes & 2 influenza B virus types contained in the vaccine.
Hypersensitivity to flu vaccine, any of the excipients, or any component that may be present as traces eg, eggs (ovalbumin, chicken proteins), formaldehyde, gentamicin sulphate & Na deoxycholate. Postpone immunisation in patients w/ febrile illness or acute infection.
Appropriate medical treatment & supervision should always be readily available in case of an anaphylactic event following vaccination. Do not administer intravascularly. Ab response in patients w/ endogenous or iatrogenic immunosuppression may be insufficient. Not effective against all possible strains of flu virus. Protective immune response may not be elicited in all vaccinees. Administer w/ caution to individuals w/ thrombocytopenia or any coagulation disorder since bleeding may occur following IM administration. False +ve results in serology tests using the ELISA method to detect Ab against HIV-1, hepatitis C & HTLV1. Safety & efficacy in childn <6 mth have not been established.
Inj site pain. Adult ≥18 yr: Fatigue; myalgia. Headache; GI symptoms; sweating; arthralgia; inj site redness/swelling/induration, shivering, fever. Childn 6-17 yr: Myalgia; fatigue, inj site redness/swelling. Headache; GI symptoms; arthralgia; fever (≥38°C), shivering, inj site induration. Childn 3-5 yr: Irritability/fussiness; inj site redness/swelling. Loss of appetite; drowsiness; fever (≥38°C), inj site induration. Childn 6 mth to 3 yr: Loss of appetite; irritability/fussiness; drowsiness; inj site redness. Fever (≥38°C), inj site swelling.
Can be concomitantly administered w/ pneumococcal polysaccharide vaccines in subjects aged ≥50 yr, or w/ adjuvanted herpes zoster vaccine (Shingrix). Administer at different inj sites if to be given at the same time as another injectable vaccine.
Sign Out
